9. Comparative characteristics of AMA-positive and AMA- negative primary biliary cholangitis

Authors

  • A. Gainutdin National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • A. Issanov National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • A. Ashimkhanova National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • N. Ashimova National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • А. Нерсесов National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • Т. Тәжібаев National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • T. Tajibayev National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан
  • I. Sagatov National Medical University, Almaty, Kazakhstan, г. Алматы, Казахстан

DOI:

https://doi.org/10.35805/BSK2023I009

Downloads

Abstract

Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is one of the most significant diseases that is predominantly verified in women. The prevalence of PBC is 1.9-40.2 per 100,000 population. Antimitochondrial antibodies (AMA) are of major importance for the diagnosis of primary biliary cirrhosis (PBC), and it has also been suggested that they may be involved in the pathogenesis of the disease. conflicts of interest

Objective: The aim of this study was to characterize the clinical, biochemical parameters and response to UDCA (Paris I criteria) PBC patients depending on AMA status in the Republic of Kazakhstan.

Material and methods. The study was conducted on the basis of the Research Institute of Cardiology and Internal Diseases from 2014 to 2019. A total of 212 patients with primary biliary cholangitis were recorded.

Results. Among 212 patients, 171 (80.7%) were AMA-positive and 41(19,3%) - AMA-negative. Vast majority of patients in both groups were Asian (179; 84.4%) and female (206; 97.2%). Severe disease (F3/4) was revealed in 108 (63.2%) AMA-positive and in 18 (43.9 %) AMA-negative patients (p>0.05). AMA-positive and AMA-negative PBC were associated with autoimmune hepatitis in 88 (51.5%) and 10 (24.4%) cases (p<0.01), rheumatoid arthritis in 26 (15.2%) and 5 (12.2%), autoimmune thyroiditis in 35 (20.5%) and 4 (9.8%), vitamin D deficiency in 89 (52.1%) and 19 (46.3%), osteoporosis in 48(28.1%) and 7 (17.1%), gallstone disease in 43 (25.4%) and 8 (21.2%) respectively (p >0.05). Response to ursodeoxycholic acid (UDCA) treatment according to Paris I criteria was noted in 24 out of 81 (29.6%) AMA-positive and in 9 out of 22 (40.9%) AMA-negative patients (p>0.05).

Conclusion. In patients with AMA-positive PBC compared with AMA-negative, there is a statistically significant high value of autoimmune hepatitis and autoimmune thyroiditis. Whereas, response to UDCA treatment according to Paris I criteria is higher in AMA-negative PBC.

Keywords

primary biliary cholangitis, cholestasis, autoimmune liver diseases

References

  1. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’ // J Hepatol. – 2015. -№63. – Р. 1285– 1287
  2. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis // Lancet. – 2011. - №377. – Р. 1600–1609
  3. Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis // Annu Rev Pathol. – 2013. - №8. – Р. 303–330
  4. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond // J Hepatol.-2015. - №62. – Р. 25–37
  5. Webb GJ, Hirschfield GM. Primary biliary cholangitis in 2016: Highdefinition PBC: biology, models and therapeutic advances // Nat Rev Gastroenterol Hepatol. – 2017. - №14. – Р. 76–78
  6. Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study // Liver Int. – 2014. -№34. – Р. 31–38
  7. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis // Semin Liver Dis. – 2014. - №34. – Р. 318–328
  8. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis // Semin Liver Dis. – 2014. - №34. – Р. 265–272
  9. Webb GJ, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity // J Autoimmun. – 2016. - №66. – Р. 25–39
  10. Bianchi I, Carbone M, Lleo A, Invernizzi P. Genetics and epigenetics of primary biliary cirrhosis // Semin Liver Dis. – 2014. - №34. – Р. 255–264
  11. Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases // Semin Liver Dis. – 2007. - №27. – Р. 161–172
  12. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1987;316:521-528
  13. Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 1991;100:822-833
  14. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 10–5
  15. Bassendine MF, Yeaman SJ. Serological markers of primary biliary cirrhosis: diagnosis, prognosis and subsets. Hepatology 1992; 15: 545–8
  16. Shi XH, Zhang FC. Antimitochondrial antibody in primary biliary cirrhosis. Chin J Rheumatol 2005; 9: 506–8
  17. Sherlock S. Primary biliary cirrhosis. In: Sherlock S, ed.Diseases of the Liver and Biliary System, 8th edn. Oxford:Scientific Publications Limited, 1989; 212–23
  18. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31: 1005–13
  19. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90: 247–9
  20. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107: 200–7

Published

2023-02-22

Issue

No. 1 (2023)

Section

Статьи